10.1097/MD.0000000000016114 Medicine
Some individuals use BPC-157 specifically for injury recovery, while others experiment with it for gastrointestinal symptoms or inflammatory conditions
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
According to a previous study 25,26 , we assigned scores of 100, 200, and 300 for anagen IIIIa, anagen IIIbIIIc, and anagen IVVI HFs, respectively
During the day, your body naturally undergoes extensive cellular repair, metabolic cleanup, and encounters the highest levels of environmental oxidative stress
doi:10.1186/s13287-022-02831-1 [2] McCoy AT, Benoist CC, Wright JW, et al
